

WHO GUIDELINES FOR THE

# Treatment of *Genital Herpes Simplex Virus*





WHO GUIDELINES FOR THE

# **Treatment of** ***Genital Herpes Simplex Virus***



World Health  
Organization

WHO Library Cataloguing-in-Publication Data

WHO guidelines for the treatment of genital herpes simplex virus

I. World Health Organization.

ISBN 978 92 4 154987 5

Subject headings are available from WHO institutional repository

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website ([http://www.who.int/about/licensing/copyright\\_form](http://www.who.int/about/licensing/copyright_form)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

# CONTENTS

<b>Acknowledgements</b>	<b>iii</b>
<b>Abbreviations and acronyms</b>	<b>iv</b>
<b>Executive summary</b>	<b>1</b>
Rationale for the guidelines	2
Objectives	2
Methods	2
Recommendations	3
<b>Overview of the guidelines for the prevention, treatment and management of STIs</b>	<b>5</b>
STI epidemiology and burden	5
Why new guidelines for the prevention, treatment and management of STIs?	5
Approach to the revision of STI guidelines	6
References	8
<b>WHO guidelines for the treatment of genital herpes simplex virus</b>	<b>9</b>
<b>1. Introduction</b>	<b>9</b>
1.1 Epidemiology, burden and clinical considerations	9
Clinical presentation	9
Laboratory diagnosis	10
1.2 Rationale for new recommendations	10
1.3 Objectives	10
1.4 Target audience	10
1.5 Structure of the guidelines	11
<b>2. Methods</b>	<b>12</b>
2.1 Guideline Development Group (GDG)	12
2.2 Questions and outcomes	12
2.3 Reviews of the evidence	12
2.4 Making recommendations	13
2.5 Management of conflicts of interest	14
<b>3. Dissemination, updating and implementation of the guidelines</b>	<b>15</b>
3.1 Dissemination	15
3.2 Updating the STI guidelines and user feedback	15
3.3 Implementation of the WHO guidelines for the treatment of genital herpes simplex virus	15
Adaptation, implementation and monitoring	15
Identifying and procuring STI medicines	16
<b>4. Recommendations for treatment of genital herpes simplex virus</b>	<b>17</b>
4.1 First clinical episode of genital HSV infection	17
Recommendation 1	17
Recommendation 2	17



## CONTENTS (CONTINUED)

<b>4.2 Recurrent clinical episode of genital HSV infection (episodic therapy)</b>	<b>18</b>
Recommendation 3	18
Recommendation 4	18
<b>4.3 Recurrent clinical episodes of genital HSV infection that are frequent, severe or cause distress (suppressive therapy)</b>	<b>20</b>
Recommendation 5	20
Recommendation 6	20
<b>5. Research implications</b>	<b>22</b>
<b>References</b>	<b>23</b>
<b>Annex A: STI guideline development teams</b>	<b>24</b>
<b>Annex B: Detailed methods for guideline development</b>	<b>33</b>
Questions and outcomes	33
Review of the evidence	36
Applying the GRADE approach to making the recommendations	38
<b>Annex C: Lists of references for reviewed evidence</b>	<b>39</b>
Recommendation 1	39
Recommendation 2	39
Recommendation 3	40
Recommendation 4	41
Recommendation 5	42
Recommendation 6	43
Recommendations for people living with HIV	43

### Web annexes available at:

[www.who.int/reproductivehealth/publications/rhis/genital-HSV-treatment-guidelines/en/](http://www.who.int/reproductivehealth/publications/rhis/genital-HSV-treatment-guidelines/en/)

**Web annex D: Evidence profiles and evidence-to-decision frameworks**

**Web annex E: Systematic reviews for genital herpes simplex virus guidelines**

**Web annex F: Summary of conflicts of interest**

## ACKNOWLEDGEMENTS

The Department of Reproductive Health and Research at the World Health Organization (WHO) would like to thank the members of the STI Guideline Development Group for their consistent availability and commitment to making these guidelines possible. The Department is also grateful to the STI External Review Group for peer reviewing these guidelines, and appreciates the contribution of the WHO Steering Committee. The names of the members of each group are listed below, with full details provided in Annex A.

Special thanks to Dr Nancy Santesso, the guideline methodologist who also led the systematic review process, for her hard work and firm commitment to the guideline development process. We also thank the members of the Systematic Review Team from McMaster University.

We appreciate the overall support of the WHO Guidelines Review Committee Secretariat during the guideline development process, with grateful thanks to Dr Susan Norris.

We thank MsTheresa Ryle for the administrative support, and 400 Communications for assistance with the guideline design and layout. This guideline document was edited by Ms Jane Patten, of Green Ink, United Kingdom.

Dr Teodora Wi led the guideline development process and Dr Nathalie Broutet co-led the process under the supervision of Dr James Kiarie and leadership of Dr Ian Askew. Mr Lee Sharkey provided support during the guideline development process.

### FUNDING

The preparation and printing of the guidelines were funded exclusively by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). No external source of funding was solicited or utilized.

### CONTRIBUTORS TO WHO GUIDELINES FOR THE TREATMENT OF GENITAL HERPES SIMPLEX VIRUS

#### STI Guideline Development Group (GDG):

**Chairpersons:** Judith Wasserheit, Holger Schünemann, Patricia Garcia

**Members:** Yaw (Sax) Adu-Sarkodie, Andrew Amato, Gail Bolan, John Changalucha, Xiang-Sheng Chen, Harrel Chesson, Craig Cohen, Francisco Garcia, Suzanne Garland, Sarah Hawkes, Mary Higgins, King Holmes, Jeffrey Klausner, David Lewis, Nicola Low, David Mabey, Angelica Espinosa Miranda, Nelly Mugo, Saiqa Mullick, Francis Ndowa, Joel Palefsky, Keith Radcliffe, Ulugbek Sabirov, Judith Stephenson, Richard Steen, Magnus Unemo, Bea Vuylsteke, Anna Wald, Thomas Wong and Kimberly A. Workowski

#### STI GDG working group for genital herpes simplex virus:

Yaw (Sax) Adu-Sarkodie, Xiang-Sheng Chen, Suzanne Garland, Jeffrey Klausner, David Lewis, Ornella Lincetto, Nelly Mugo, Saiqa Mullick, Francis Ndowa, Joel Palefsky, Anna Wald, Thomas Wong

#### STI External Review Group:

Laith Abu-Raddad, Chris Akolo, Adele Schwartz Benzaken, Mircea Betiu, Anupong Chitwarakorn, Carolyn Deal, Margaret Gale-Rowe, William M. Geisler, Amina El Kettani, Mizan Kiros, Ahmed Latif, Philippe Mayaud, David McCartney, Ali M. Mir, Nuriye Ortayli, Khantanouvieng Sayabounthavong and Aman Kumar Singh

#### WHO Steering Committee:

**WHO regional offices:** Massimo Ghidinelli, Hamida Khattabi, Lali Khotenashvili, Ornella Lincetto, Ying-Ru Lo, Frank Lule and Razia Pendse

**WHO headquarters:** Moazzam Ali, Avni Amin, Rachel Baggaley, Venkatraman Chandra-Mouli, Jane Ferguson, Mario Festin, Mary Lyn Gaffield, Antonio Gerbase, Sami Gottlieb, Frances McConville, Lori Newman, Annette Mwansa Nkowane, Anita Sands, Igor Toskin and Marco Vitoria

**WHO STI Secretariat:** Ian Askew, Teodora Elvira Wi (lead, development of the guidelines), Nathalie Broutet (co-lead, development of the guidelines), James Kiarie and Lee Sharkey

**Systematic Review Team:** Nancy Santesso (lead), Housne Begum, Janna-Lina Kerth, Gian Paolo Morgano, Kristie Poole, Nicole Schwab, Matthew Ventresca, Yuan Zhang and Andrew Zikic (members)

**Methodologist:** Nancy Santesso.

## ABBREVIATIONS AND ACRONYMS

<b>AIDS</b>	acquired immune deficiency syndrome
<b>AMR</b>	antimicrobial resistance
<b>CI</b>	confidence interval
<b>DOI</b>	declaration of interests
<b>GDG</b>	Guideline Development Group
<b>GRADE</b>	Grading of Recommendations Assessment, Development and Evaluation
<b>GUD</b>	genital ulcer disease
<b>HIV</b>	human immunodeficiency virus
<b>HPV</b>	human papillomavirus
<b>HRP</b>	UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction
<b>HSV</b>	herpes simplex virus
<b>HSV-1</b>	herpes simplex virus type 1
<b>HSV-2</b>	herpes simplex virus type 2
<b>MSH</b>	Management Sciences for Health
<b>MSM</b>	men who have sex with men
<b>NAAT</b>	nucleic acid amplification test
<b>PICO</b>	population, intervention, comparator, outcome

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27086](https://www.yunbaogao.cn/report/index/report?reportId=5_27086)

